Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by HuntNGatheron Feb 14, 2014 12:56pm
290 Views
Post# 22210947

I missed this one in the news. Nice association to have

I missed this one in the news. Nice association to haveThey announced on Jan 31 that James Parson (CFO of SCT) is also now the CFO at the CCRM. That is certainly interesting and reassuring. Standing so close to the fire is bound to create even more positive connections for little SSS as we get poised for the next moves. https://www.marketwired.com/press-release/ccrm-introduces-new-leadership-to-drive-company-creation-strategy-1874488.htm
Bullboard Posts